Bristol Myers Squibb Company
BMYHealthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- +6.93%
- EPS
- −2.78%
- Free cash flow
- −36.0%
- Total debt
- −12.5%
Quarter to September 2026, against a year earlier
Follow BMY
Alert me
Bristol Myers Squibb Company 10-Q filed Jul 31, 2025
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 24, 2025: 28 added · 11 removed · 56 modified; 11 with only figures updated
-
Modified · EXECUTIVE SUMMARY
During the first quarter ofIn 2025, we have achieved multiple regulatory approvals across our portfolio, including the: (i) approval of Breyanzi forOpdivo + Yervoyadults with relapsed or refractory FL in the EU, (ii) approval of Camzyos for the treatment of symptomatic obstructive HCM in Japan, (iii) approval of Opdivo + Yervoy as a first-line treatment of adult patients with unresectable or advancedhepatocellular carcinomaHCC in both the U.S. and the EU, (iiiv) approvalfor Breyanzi in the EUof Opdivo + Yervoy for first-line treatment of adultswith relapsed or refractory FLand pediatric patients 12 years and(iii) approval for Camzyos for the treatment of symptomatic obstructive HCMolder with unresectable or metastatic MSI-H or dMMR colorectal cancer inJapan. Additionallythe U.S.,in April 2025, we achieved two approvals(v) approval of Opdivo as a perioperative regimen forOpdivo + Yervoyresectable high risk NSCLC in theU.S. for the treatmentEU and (vi) approval ofadults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer and the treatment of adult patientsOpdivo Qvantig for use across multiple adult solid tumors in the EU. Additionally, we received label updates from the FDA that have reduced or removed certain patient monitoring requirements associated withunresectable or metastatic hepatocellular carcinomathe use of Camzyos, Breyanzi and Abecma.